---
title: "Incyte (INCY) stock news, pipeline, cash and catalysts"
url: "https://aibio.space/companies/incyte/"
publisher: "aibio.space (Biotech Investor Relations News)"
summary: "Incyte news for investors: Incyte is a commercial-stage drugmaker that sells Jakafi for blood cancers and graft-versus-host disease, the skin cream…"
---

Desk view · Opinion · Updated Oct 22, 2026

## Incyte has the cash and two years to replace Jakafi

Incyte is profitable and cash-rich, but still depends on Jakafi for most of its sales and has about two years to build replacements. Its Q2 growth was boosted by a one-time CMS settlement item. Pipeline decisions in the first quarter of 2027 and the Vega, Genesis and Edison deals will show whether the transition works.

Read the full desk view

aibio.space Investor Rank · Opinion

**7** /10 Positive view

Profitable and cash-rich, but Jakafi was 71% of product revenue and loses exclusivity from late 2028, and second-quarter growth leaned on a one-time item.

- **Technology**: 2/2

- **Odds**: 1/2

- **Balance sheet**: 2/2

- **Risk**: 1/2

- **Momentum**: 1/2

Opinion only. The Investor Rank is aibio.space's opinion of the company's business position, drawn from the public sources on this page. It is not a recommendation to buy, sell or hold any security and it is not investment advice. It does not consider the share price, valuation or your circumstances, and it can change at any time. Payments from companies never affect it. [How the rank works](https://aibio.space/disclosures/#rank).

- **Technology**: **Proven franchise, wider pipeline.** Jakafi and Opzelura are established JAK products, and Incyte is adding povorcitinib, a mutCALR antibody and a KRAS G12D inhibitor.

- **Odds**: **Near-term decisions are scheduled.** Povorcitinib and Monjuvi both have U.S. approvals targeted for Q1 2027, while the mutCALR program is earlier-stage.

- **Balance sheet**: **Strong and profitable.** Incyte held $4.5 billion at June 30 and reported $585.6 million of GAAP net income in Q2, though a $1.27 billion Vega charge arrives in Q3.

- **Main risk**: **Jakafi cliff.** Jakafi was 71% of 2025 net product revenue and loses exclusivity between late 2028 and early 2029.

- **Watch next**: **Q4 readouts and ESMO.** Opzelura HS and povorcitinib prurigo nodularis phase 3 data are due in Q4 2026, with ESMO presentations Oct. 23-27.

## Top news on Incyte

## Dates

**Oct. 23-27, 2026**
ESMO Congress presentations of phase 1 data for INCB161734, INCA33890 and INCB123667 [Source](https://www.sec.gov/Archives/edgar/data/0000879169/000087916926000053/incy-q22026xexx991.htm)

**Q4 2026**
Phase 3 topline data for Opzelura in hidradenitis suppurativa (TRuE-HS1/HS2) and povorcitinib in prurigo nodularis (STOP-PN1/PN2) [Source](https://www.sec.gov/Archives/edgar/data/0000879169/000087916926000053/incy-q22026xexx991.htm)

**Q1 2027**
Targeted U.S. approval of povorcitinib in hidradenitis suppurativa and U.S. launch of Monjuvi in newly diagnosed DLBCL [Source](https://www.sec.gov/Archives/edgar/data/0000879169/000087916926000053/incy-q22026xexx991.htm)

**H1 2027**
Planned vitiligo filing for povorcitinib [Source](https://investor.incyte.com/node/26526/pdf)

## The money

$4.5 billion in cash and marketable securities at June 30, 2026, up from $3.6 billion at Dec. 31, 2025. The Vega acquisition (closed July 2026, $1.25 billion upfront) will be charged in Q3. No runway guidance; the company is profitable. [Source](https://www.sec.gov/Archives/edgar/data/0000879169/000087916926000053/incy-q22026xexx991.htm)

Q2 2026 total revenue $1.67 billion (up 38%); net product sales $1.49 billion, of which Jakafi/Jakafi XR $817 million and Opzelura $450 million (including a $246 million one-time, non-cash benefit). Excluding that item, net sales grew 17%. [Source](https://www.sec.gov/Archives/edgar/data/0000879169/000087916926000053/incy-q22026xexx991.htm)

## Risks on the record

- Jakafi was 71% of Incyte's nearly $4.4 billion in 2025 net product revenue and loses exclusivity between late 2028 and early 2029. [Source](https://www.biopharmadive.com/news/incyte-vega-acquisition-star-biotech-deal-blood-disorder-vwd/822238/)
- Q2 Opzelura sales included a one-time $246 million benefit from a CMS settlement; underlying Opzelura growth was 24% and total net sales growth excluding it was 17%. [Source](https://www.sec.gov/Archives/edgar/data/0000879169/000087916926000053/incy-q22026xexx991.htm)
- Povorcitinib's vitiligo results (18.9% F-VASI75 in both trials) trail AbbVie's Rinvoq, which is already filed, in placebo-adjusted terms. [Source](https://www.fiercebiotech.com/biotech/incytes-jak-inhibitor-scores-phase-3-vitiligo-wins-cant-quite-shake-rinvoq)

## Questions investors ask

### What is aibio.space's Investor Rank for Incyte?

7 out of 10, our positive view. Profitable and cash-rich, but Jakafi was 71% of product revenue and loses exclusivity from late 2028, and second-quarter growth leaned on a one-time item. This is opinion only, not a recommendation to buy, sell or hold, and it does not consider the share price or valuation. [Source](https://aibio.space/disclosures/#rank)

### Why did Incyte raise its 2026 guidance?

On July 28, 2026 Incyte raised net sales guidance to $5,130 million to $5,260 million after a CMS settlement on Medicaid rebates for Opzelura. Q2 included a $246 million one-time, non-cash benefit; excluding it, net sales rose 17%. [Source](https://www.sec.gov/Archives/edgar/data/0000879169/000087916926000053/incy-q22026xexx991.htm)

### What is Incyte buying from Vega Therapeutics?

Incyte agreed on June 8, 2026 to acquire Vega for $1.25 billion upfront and up to $750 million in sales milestones. The prize is latarcibart (VGA039), a once-monthly self-injected antibody in phase 3 for von Willebrand disease. [Source](https://www.biopharmadive.com/news/incyte-vega-acquisition-star-biotech-deal-blood-disorder-vwd/822238/)

### When does Jakafi lose exclusivity?

Incyte has said Jakafi loses exclusivity between late 2028 and early 2029, according to Fierce Pharma. Jakafi made 71% of Incyte's nearly $4.4 billion in net product revenue last year. [Source](https://www.fiercepharma.com/pharma/boosted-cms-settlement-incyte-expects-opzelura-cross-1b-2026)

### What is Jakafi XR?

Jakafi XR is a once-daily extended-release ruxolitinib tablet the FDA approved on May 1, 2026 for myelofibrosis, polycythemia vera and graft-versus-host disease. A 55 mg tablet once daily matched 25 mg of Jakafi twice daily on exposure. [Source](https://investor.incyte.com/node/26571/pdf)

### When could povorcitinib be approved?

The FDA accepted Incyte's NDA for povorcitinib in hidradenitis suppurativa in the first quarter of 2026. Incyte targets U.S. approval and launch in the first quarter of 2027. [Source](https://investor.incyte.com/node/26526/pdf)

### What is Incyte's market cap?

We do not publish live share prices. In its annual report, Incyte Corporation put the market value of shares held by non-affiliates (public float) at $11.20 billion as of Jun 30, 2025. Source

### Is Incyte a smaller reporting company?

SEC records list Incyte Corporation's filer category as: Large accelerated filer. Source

### Where is Incyte headquartered?

SEC records list its business address as 1801 AUGUSTINE CUT-OFF, WILMINGTON, DE, 19803. Source

### When does Incyte's fiscal year end?

Incyte Corporation's fiscal year ends on December 31, per SEC records. Source

### What did Incyte last file with the SEC?

Its most recent filing in our record is an 8-K filed 2026-08-31. All of its filings are on SEC EDGAR. [Source](https://www.sec.gov/Archives/edgar/data/879169/000087916926000058/incy-20260831.htm)

### What was Incyte called before?

SEC records list these former names: INCYTE INC; INCYTE GENOMICS INC; INCYTE PHARMACEUTICALS INC. Source

### What industry is Incyte in?

Its SEC industry code (SIC 8731) is Services-Commercial Physical & Biological Research. Source

## Legal and investor matters

Checked against Incyte filings and press releases. Allegations are allegations; nothing here is a finding of fault. Reviewed Oct 25, 2026.

Item 3 of the 10-K filed 2026-02-10 states that Incyte does not expect any current legal proceedings to have a material adverse impact on its business or financial condition. It covers that annual report only. [Source](https://www.sec.gov/Archives/edgar/data/879169/000087916926000010/incy-20251231.htm)

1. 2026-08-31 Regulatory Incyte signs CMS agreement on Jakafi Medicaid pricing Incyte reported in an 8-K that it entered into an agreement with the U.S. Centers for Medicare & Medicaid Services. Under it, Incyte will let state Medicaid programs buy Jakafi and Jakafi XR at prices aligned with a defined group of other advanced nations. The company expects not to be subject to certain future CMS pricing mandates, including the proposed GUARD and GLOBE models, and does not expect an effect on its 2026 guidance. [Incyte Form 8-K, 2026-08-31](https://www.sec.gov/Archives/edgar/data/879169/000087916926000058/incy-20260831.htm)
2. 2026-06-22 Litigation Incyte resolves CMS suit over Opzelura Medicaid rebate rule Incyte announced an agreement with CMS to resolve its lawsuit over how Medicaid rebate rules apply to Opzelura cream. CMS will not treat Opzelura as a line extension of Jakafi, and Incyte withdrew the suit. The company expected a one-time non-cash benefit of about $246 million in the quarter ended June 30, 2026, from reversing accrued balances. The 10-Q filed 2026-07-28 records a benefit of $246.0 million. Status: settled [Incyte Form 8-K, 2026-06-22](https://www.sec.gov/Archives/edgar/data/879169/000087916926000046/incy-20260622.htm)
3. 2025-05-11 Litigation Incyte settles Novartis royalty litigation for $280 million On May 11, 2025, Incyte and Novartis Pharma AG entered into a settlement agreement over litigation Novartis initiated about the duration of royalties Incyte owes under their 2009 collaboration agreement. Incyte agreed to pay Novartis $280.0 million to settle disputed royalties on U.S. Jakafi net sales through December 31, 2024. The parties also agreed to cut the U.S. Jakafi royalty rate by 50% from January 1, 2025, for a period defined in the agreement. As of March 31, 2025 Incyte had accrued about $537.1 million for the dispute, and said it would record the $242.2 million difference in its second-quarter 2025 results. Status: settled [Incyte Form 8-K, 2025-05-14](https://www.sec.gov/Archives/edgar/data/879169/000087916925000059/incy-20250511.htm)

## Pipeline

| Program | Indication | Stage |
|---|---|---|
| Jakafi / Jakafi XR (ruxolitinib) | Myelofibrosis, polycythemia vera, graft-versus-host disease | Marketed; Jakafi XR once-daily version approved May 1, 2026 [Source](https://investor.incyte.com/node/26571/pdf) |
| Povorcitinib (oral JAK inhibitor) | Hidradenitis suppurativa | NDA accepted by FDA in Q1 2026; U.S. approval targeted Q1 2027 [Source](https://investor.incyte.com/node/26526/pdf) |
| Opzelura (ruxolitinib cream) | Vitiligo and other skin conditions (marketed); hidradenitis suppurativa (phase 3) | Marketed; phase 3 TRuE-HS1/HS2 topline expected Q4 2026 [Source](https://www.sec.gov/Archives/edgar/data/0000879169/000087916926000053/incy-q22026xexx991.htm) |
| Monjuvi / Minjuvi (tafasitamab) | Newly diagnosed DLBCL | Global submissions accepted Q2 2026; U.S. approval and launch anticipated Q1 2027 [Source](https://www.sec.gov/Archives/edgar/data/0000879169/000087916926000053/incy-q22026xexx991.htm) |
| INCA033989 (mutCALR antibody) | Essential thrombocythemia, myelofibrosis | Phase 3 EXCALIBUR-ET2 started mid-2026 [Source](https://www.sec.gov/Archives/edgar/data/0000879169/000087916926000053/incy-q22026xexx991.htm) |
| Latarcibart (VGA039) | Von Willebrand disease | Phase 3 VIVID-6; data expected early 2029 [Source](https://www.genengnews.com/topics/translational-medicine/incyte-to-acquire-vega-therapeutics-for-up-to-2b-growing-hematology-pipeline-with-phase-iii-vwd-candidate/) |

Opinion · Devil's advocate

## Fact-check-o-meter

Some gaps

Incyte's numbers hold up, but the releases skip the 2028 Jakafi patent expiry

Incyte's 2026 releases match its 10-Q on the figures, and the one-time Opzelura benefit is disclosed up front. The gaps are in emphasis: the growth story leaves out the 2028 Jakafi patent expiry the filing calls out, and the newest hematology asset rests so far on an open-label, single-arm phase 3 design.

1. Press release vs filing · weight low Headline growth leans on a one-time CMS benefit **The company said:** "Total revenue of $1.67 billion and total net sales of $1.49 billion in the second quarter of 2026, an increase of 38% and 40%, respectively, compared to the second quarter of 2025" [source](https://www.sec.gov/Archives/edgar/data/879169/000087916926000053/incy-q22026xexx991.htm) **The record says:** The 10-Q says the quarter's Opzelura sales include a one-time, non-cash benefit of $246.0 million from the agreement with CMS "to resolve our litigation related to the application of Medicaid rebate rules to OPZELURA", tied to "the reversal of previously established accrual balances through March 31, 2026". [source](https://www.sec.gov/Archives/edgar/data/879169/000087916926000056/incy-20260630.htm) **Our view:** This is disclosed fairly. The release's second bullet gives the 17% growth figure without the benefit, and the 38% headline includes the benefit.
2. Press release vs filing · weight medium Growth message, no mention of the 2028 Jakafi patent expiry **The company said:** "With ten data readouts expected in the second half of 2026, alongside product launches through early next year, we are well positioned for our next phase of growth." [source](https://www.sec.gov/Archives/edgar/data/879169/000087916926000053/incy-q22026xexx991.htm) **The record says:** The 10-Q risk factors state: "we expect that JAKAFI product sales will begin to decline upon the expiration of our patent exclusivity in 2028." Jakafi was $817 million of the quarter's $1.49 billion in net sales, and the filing adds that patent suits against several generic filers "remain pending." [source](https://www.sec.gov/Archives/edgar/data/879169/000087916926000056/incy-20260630.htm) **Our view:** The Q2 release never mentions 2028 or the pending generic suits. Jakafi was about 55% of the quarter's net sales, and the filing ties its expected decline to 2028, which the release's growth message does not mention.
3. Science · weight medium Povorcitinib wins in vitiligo, but fewer than 1 in 5 responded **The company said:** "In STOP-V1, 18.9% of povorcitinib-treated patients achieved a >75% reduction in F-VASI75 compared to 6.8% of placebo-treated patients at Week 52 (p<0.001)." [source](https://www.sec.gov/Archives/edgar/data/879169/000087916926000023/incy-q12026xexx991.htm) **The record says:** ClinicalTrials.gov lists STOP-V1 as randomized and triple-masked with 467 participants, and the primary outcome is the proportion achieving F-VASI75 at Week 52, the same endpoint the release reports. Placebo patients switch to povorcitinib for a second 52 weeks. [source](https://clinicaltrials.gov/study/NCT06113445) **Our view:** The trial is randomized and triple-masked, and the registered primary endpoint matches the one the release reports. The issue is size of effect: placebo-adjusted gains of about 12 and 16 points leave most patients short of the goal, and any comparison with other vitiligo drugs will be cross-trial.
4. Science · weight medium Latarcibart called 'potentially transformative' while the phase 3 is single-arm **The company said:** "We also recently strengthened our Hematology franchise through the acquisition of latarcibart, a potentially transformative medicine for von Willebrand disease currently in Phase 3 development." [source](https://www.sec.gov/Archives/edgar/data/879169/000087916926000053/incy-q22026xexx991.htm) **The record says:** The registry calls VIVID-6 "A Prospective, Multicenter, Open-label, Phase 3 Clinical Study" with masking listed as none and 60 planned participants. Each patient's own observation period serves as the comparison: "an initial observational period, during which participants are monitored without receiving study drug, followed by an interventional period". The release says topline data are due in early 2029. [source](https://clinicaltrials.gov/study/NCT07115004) **Our view:** The 81% bleeding-rate cut cited in the release comes from a phase 1/2 study, and the phase 3 has no randomized control. That design can support approval in a rare bleeding disorder, but bleed counts in open-label studies are open to reporting bias, and the release expects an IPR&D expense of about $1,270 million in the third quarter of 2026 for the deal, well before 2029 data.
5. Legal and disclosure record · weight low No securities litigation or enforcement disclosed **The record says:** Legal Proceedings in the 10-Q points to Note 15, which lists the now-settled Incyte suit against CMS over the Medicaid line extension rule and "various patent disputes and litigation initiated by us related to potential generic or other competition for our products" (Jakafi and Opzelura ANDA suits in the District of New Jersey). No securities litigation or enforcement disclosed in the latest filing. An Aug. 31 8-K adds a CMS pricing agreement for Jakafi in Medicaid that the company does not expect to affect 2026 guidance. [source](https://www.sec.gov/Archives/edgar/data/879169/000087916926000056/incy-20260630.htm) **Our view:** The legal docket is patent defense the company started, plus a pricing dispute resolved by an agreement with CMS. Outcomes of the remaining Jakafi generic suits matter most for the timing of the 2028 decline.

Documents we compared

- [Incyte Q2 2026 results press release (8-K Ex. 99.1)](https://www.sec.gov/Archives/edgar/data/879169/000087916926000053/incy-q22026xexx991.htm) 2026-07-28
- [Incyte Q1 2026 results and vitiligo phase 3 release](https://investor.incyte.com/node/26526/pdf) 2026-04-28
- [Incyte Form 10-Q for quarter ended June 30, 2026](https://www.sec.gov/Archives/edgar/data/879169/000087916926000056/incy-20260630.htm) 2026-07-28
- [Incyte Form 8-K, CMS agreement](https://www.sec.gov/Archives/edgar/data/879169/000087916926000058/incy-20260831.htm) 2026-08-31
- [ClinicalTrials.gov NCT06113445 (STOP-V1)](https://clinicaltrials.gov/study/NCT06113445) 2026-08-25
- [ClinicalTrials.gov NCT07115004 (VIVID-6)](https://clinicaltrials.gov/study/NCT07115004) 2026-10-23

This is opinion. We compare the company's own announcements with its filings and the scientific record, and link every source. It is not an allegation of wrongdoing and not investment or legal advice. Legal items list only matters disclosed in filings or by courts and regulators. Checked Oct 23, 2026. Companies can respond through our [right of reply](https://aibio.space/reputation/#reply).

## Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:INCY on TradingView](https://www.tradingview.com/symbols/NASDAQ-INCY/).

## SEC filings and registration

- **SEC name**: Incyte Corp

- **CIK**: 879169

- **Industry (SIC)**: Services-Commercial Physical & Biological Research (8731)

- **US tickers**: INCY (Nasdaq)

- **State or country of incorporation**: DE

- **Fiscal year ends**: December 31

- **Filer category**: Large accelerated filer

- **Business address**: 1801 AUGUSTINE CUT-OFF, WILMINGTON, DE, 19803

- **Phone**: 3024986700

- **Former names**: INCYTE INC; INCYTE GENOMICS INC; INCYTE PHARMACEUTICALS INC

### Recent filings (8-K and 6-K are the company's own announcements)

- [8-K](https://www.sec.gov/Archives/edgar/data/879169/000087916926000058/incy-20260831.htm) filed 2026-08-31
- [10-Q](https://www.sec.gov/Archives/edgar/data/879169/000087916926000056/incy-20260630.htm) filed 2026-07-28
- [8-K](https://www.sec.gov/Archives/edgar/data/879169/000087916926000053/incy-20260728.htm) filed 2026-07-28
- [8-K](https://www.sec.gov/Archives/edgar/data/879169/000087916926000048/incy-20260706.htm) filed 2026-07-06
- [8-K](https://www.sec.gov/Archives/edgar/data/879169/000087916926000046/incy-20260622.htm) filed 2026-06-22
- [8-K](https://www.sec.gov/Archives/edgar/data/879169/000087916926000043/incy-20260608.htm) filed 2026-06-09
- [8-K](https://www.sec.gov/Archives/edgar/data/879169/000087916926000040/incy-20260608.htm) filed 2026-06-08
- [DEF 14A](https://www.sec.gov/Archives/edgar/data/879169/000087916926000031/incy-20260428.htm) filed 2026-04-28

Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000879169), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.

Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update)

---
Source page: https://aibio.space/companies/incyte/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Incyte (INCY) stock news, pipeline, cash and catalysts", 2026-10-31, https://aibio.space/companies/incyte/